Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 8/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.51 |
| ▸ | RXRA | P19793 | 7/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471306 | 0.93 | RXRA (0.49) | NR1H2NR1H3RXRAPTGS2HTR2A | |
| SCHEMBL3473004 | 0.90 | RXRA (0.50) | NR1H2NR1H3RXRAPTGS2 | |
| SCHEMBL3470968 | 0.89 | RXRA (0.49) | NR1H2NR1H3RXRAPTGS2KDM4E | |
| SCHEMBL3472970 | 0.88 | NR1H2 (0.56) | NR1H2NR1H3RXRAPTGS2SYK | |
| SCHEMBL3472146 | 0.88 | NR1H2 (0.56) | NR1H2NR1H3RXRAPTGS2SYK | |
| SCHEMBL3471933 | 0.87 | NR1H2 (0.57) | NR1H2NR1H3RXRAPTGS2SYK | |
| SCHEMBL3471781 | 0.87 | NR1H2 (0.51) | NR1H2NR1H3RXRAPTGS2 | |
| SCHEMBL3474390 | 0.85 | NR1H2 (0.56) | NR1H2NR1H3RXRAPTGS2SYK | |
| SCHEMBL3473220 | 0.85 | NR1H2 (0.52) | NR1H2NR1H3RXRAPTGS2GALR3 | |
| SCHEMBL3473347 | 0.84 | NR1H2 (0.55) | NR1H2NR1H3RXRAPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | claimed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885RXRA 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.